Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: lung carcinoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria
For pre-surgical patients
Suspected diagnosis of resectable non-small cell lung cancer; patients with squamous cell carcinoma are eligible only if the registering site has EA5142 institutional review board (IRB) approved
Suspected clinical stage of IIIA, II or large IB (defined as size >= 4cm)
For post-surgical patients
Completely resected non-small cell lung cancer; patients with squamous cell carcinoma are eligible only if the registering site has EA5142 IRB approved
Pathologic stage IIIA, II or IB (defined as size >= 4 cm)
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Completely resected NSCLC; patients with squamous cell carcinoma are eligible only if the registering site has EA5142 IRB approved
Pathologic stage IIIA, II, or large IB (defined as size >= 4 cm)
Tissue available for the required analyses
In order to allow for time for central genotyping and eligibility for the ALCHEMIST treatment trial, patients must register within the following eligibility windows, depending on the adjuvant treatment approach:
If no adjuvant therapy, register patient within 75 days following surgery
If adjuvant chemotherapy only, register patient within 225 days following surgery
If adjuvant chemotherapy and radiation, register patient within 285 days following surgery
Exclusion Criteria
Patients who have received neoadjuvant therapy (chemo- or radio-therapy) for this lung cancer
Prior or concurrent malignancies within 5 years, except non-melanoma skin carcinoma or in situ carcinomas; a secondary primary lung cancer is considered a concurrent malignancy and would make a patient ineligible for A151216
Prior treatment with agents targeting EGFR mutation, ALK rearrangement, and PD-1/PD-L1/CTLA-4
Patients known to be pregnant or lactating
Patients with recurrence of lung cancer after prior resection

Recruitment Status

Open

Contact the research team to learn more about this study.

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176